Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Returns
Return on assets-39.4%-67.2%-84.3%
Liquidity
Current ratio13.8×+2.6×10.3×-0.5×11.4×-12.3×11.1×-46.7×11.2×-18.6×
Quick ratio13.8×+2.6×10.3×-0.5×11.4×-12.3×11.1×-46.7×11.2×-18.6×
Cash ratio13.4×+2.4×10×-0.5×11.3×-7.4×11×-15.7×11×+3.8×
Leverage
Debt-to-equity
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$13.48+99.7%$4.16-86.2%$4.91+101%$5.79+101%$6.75+102%
Valuation
Market capitalization$184.2M+72.6%$123.71M$117.16M
Enterprise value-$7.49M-127%$65.21M$47.51M
Price / book-0.4×2.2×1.8×
Free cash flow yield-27.5%+29.8pp-41.9%-54.4%
Earnings yield-31.8%+24.5pp-48.1%-54.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do OnKure Therapeutics, Inc.'s ratios come from?
Every ratio is computed from OnKure Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.